

**ASSOCIATION OF VA HEMATOLOGY/ONCOLOGY**  
 10<sup>th</sup> ANNUAL MEETING  
 September 12-14, 2014  
 Portland, Oregon

**PROGRAM AGENDA**

**FRIDAY, SEPTEMBER 12, 2014**

TIME	EVENT/TALK	SPEAKER/MODERATOR
1:00 – 6:00 pm	Registration	
1:00 – 6:00 pm	Exhibitor Set-up	
1:00 – 3:00 pm	AVAHO Board Meeting	

**LYMPHOMA MINI-SYMPOSIUM**  
 Moderator - Maria Ribeiro, MD  
 (3:00 – 5:00 PM)

<b>3:00 – 3:35 pm</b>	<b>NOVEL THERAPY FOR HODGKIN LYMPHOMA</b> <i>Objectives:</i> 1. Explain current management strategies for newly diagnosed and relapsed patients with HL 2. Describe opportunities for using novel approaches to HL 3. Review surveillance of patients with HL	<b>Christopher Flowers, MD</b> Director, Lymphoma Program Medical Director, Oncology Data Center; Associate Professor, Bone Marrow and Stem Cell Transplantation Winship Cancer Institute Emory University, Atlanta, GA
<b>3:35 – 4:10 pm</b>	<b>TARGETED THERAPY OF CHRONIC LYMPHOCYTIC LEUKEMIA</b> <i>Objectives:</i> 1. Discuss an overview of new insights into the pathogenesis and treatment of CLL. 2. Interpret molecular targets in CLL. 3. Discuss advantages and disadvantages of targeted treatment options for their patients.	<b>Adrian Wiestner, MD, PhD</b>  Head, Lymphoid Malignancies Section, Hematology Branch, NHLBI, NIH
<b>4:10 – 4:45 pm</b>	<b>MANTLE CELL LYMPHOMA UPDATE – NEW PARADIGMS</b> <i>Objectives:</i> 1. Outline current treatment approaches to newly diagnosed patients with MCL 2. Explain new therapies approved for patients with relapsed MCL 3. Delineate emerging concepts and new targets in MCL	<b>Mark Roschewski, MD</b>  Staff Clinician, Lymphoid Malignancies Branch, Center for Cancer Research National Cancer Institute, NIH
<b>4:45 – 5:00 pm</b>	<b>PANEL DISCUSSION</b>	

**CONCURRENT SESSION FOR TUMOR REGISTRARS**

Moderator: Barbara Cunningham, CTR  
(3:00 – 5:00 PM)

<b>3:00 – 4:00 pm</b>	<b>CAN WE JUMP THE HURDLES?</b>	<b>1. Donna Connery, CTR 2. Barb Cunningham, CTR</b>
	<p><i>Objectives:</i></p> <ol style="list-style-type: none"> <li><i>1. Communication within your facility</i></li> <li><i>2. Identify who to turn to for information</i></li> <li><i>3. Understand how to provide information and education to members of the cancer team</i></li> </ol>	<ol style="list-style-type: none"> <li>1. Lead Cancer Registrar VA Connecticut Healthcare System</li> <li>2. Lead Cancer Registrar (Retired), Buffalo VA Medical Center</li> </ol>
<b>4:00 – 5:00 pm</b>	<b>PREPARING FOR ACOS SURVEY</b>	<b>Connie R. Grace, CTR</b>
	<p><i>Objective:</i></p> <ol style="list-style-type: none"> <li><i>1. Outline activities to ensure program readiness for Commission on Cancer (CoC) survey.</i></li> <li><i>2. Learn how to develop a multidisciplinary team approach to the CoC survey.</i></li> <li><i>3. Review the successes and challenges in providing a high quality complete Survey Application Record (SAR).</i></li> </ol>	Grace Registry, Inc. Reston, Washington

5:00 – 6:30 pm  
6:30 – 7:30 pm  
7:30 – 8:30 pm

**SOCIAL NETWORKING**  
**WELCOME RECEPTION**  
**IMPROVING VETERAN ACCESS TO NCI COOPERATIVE TRIALS IN VHA**

*Objectives:*

- 1. Describe the barriers preventing access to important clinical trials in oncology to our veterans.*
- 4. Become aware of the people, programs and policy and that must be and/or have been engaged to improve the ability of VA Medical Centers to readily open and make available NCI Cooperative Group trials.*
- 5. Describe ongoing efforts by the SWOG-VA Working Group to effect change in VHA and provide information about resources, tools and solutions to improve the ability for Medical Centers to open Cooperative Group trials.*

PORTLAND ART MUSEUM  
**Stephen Bartlett, RPh, MSPH**

Research Pharmacy Manager  
Investigational Drug and  
Specialty Pharmacy Section  
Eastern Colorado Health Care  
System  
Co-Chair, VA Central IRB,  
Washington, D.C.  
Assistant Professor, School of  
Medicine, University of  
Colorado, Denver

**SATURDAY, SEPTEMBER 13, 2014**

<b>TIME</b>	<b>EVENT/TALK</b>	<b>SPEAKER/MODERATOR</b>
7:00 – 5:00 pm	Registration	
7:00 – 5:00 pm	Exhibit Displays	
7:00 – 5:00 pm	General Poster Session	
7:00 – 8:30 am	Breakfast Buffet	

7:50 – 8:00 am

**WELCOME/INTRODUCTION**

**Sean Cosgriff, PharmD –  
President, AVAHO**

<b>SESSION I - ESOPHAGEAL CANCER</b> Moderator: Steven Krasnow, MD (8:00 – 9:30 AM)		
<b>8:00 – 8:05 am</b>	<b>PATIENT</b>	
<b>8:05 – 8:25 am</b>	<b>MEDICAL MANAGEMENT OF ESOPHAGEAL CANCER</b>	<b>Steven Krasnow, MD</b>
	<i>Objectives:</i> 1. Generalize the impact of chemotherapy in esophageal carcinoma. 2. Review randomized clinical trials in esophageal carcinoma. 3. Describe putative biomarkers and investigational approaches to esophageal carcinoma.	Chief, Oncology, VA Medical Center, Washington DC
<b>8:25 – 8:45 am</b>	<b>RADIATION THERAPY IN MULTIDISCIPLINARY MANAGEMENT OF ESOPHAGEAL CANCER</b>	<b>Olubunmi Abayomi, MD</b>
	<i>Objectives:</i> 1. Distinguish the indications and selection of patients for radiation therapy. 2. Interpret the design and selection of radiation treatment techniques. 3. Delineate the outcomes of radiation treatment in esophageal cancer.	Radiation Oncologist, VA Medical Center, Washington, DC. Associate Professor of Radiation Oncology, Virginia Commonwealth University, Richmond, VA
<b>8:45 – 9:05 am</b>	<b>SURGICAL PERSPECTIVE TO MANAGING ESOPHAGEAL CANCER</b>	<b>Peter C. Wu, MD, FACS</b>
	<i>Objectives:</i> 1. Describe surgical management of esophageal cancer. 2. Describe complications of neoadjuvant therapy in esophageal cancer. 3. Describe appropriate management of the unsuspected positive margins.	Director, VISN20, Associate Professor of Surgery Section of Surgical Oncology University of Washington, Seattle, WA
<b>9:05 – 9:25 am</b>	<b>SKIN CONSIDERATIONS RELATED TO OSTOMY MANAGEMENT</b>	<b>Cathryn Vogeley, RN, MSN, CNS, CWCN-AP, COCN</b>
	<i>Objective:</i> 1. Describe two common skin problems associated with ostomy 2. Describe two effective interventions for these problems	Wound Program Coordinator Portland VAMC, Portland, OR
<b>9:25 – 9:30 am</b>	<b>PANEL DISCUSSION</b>	

SESSION II: USING VA DATA FOR CANCER CARE AND RESEARCH		
Moderator: Denise Hynes, MPH, Ph.D, RN (10:00 – 12:00 PM)		
<b>10:00 – 10:25 am</b>	<b>LUNG CANCER SCREENING</b>	<b>Michael Kelley, MD</b>
	<p><i>Objectives:</i></p> <ol style="list-style-type: none"> <li>1. Interpret cancer screening and inherent biases of uncontrolled trials.</li> <li>2. Appraise the completed lung cancer screening trials.</li> <li>3. Generalize data from completed lung cancer screening trials to practice in VHA.</li> </ol>	<p>National Program Director for Oncology/SCS/PCS Chief, Hematology/Oncology Durham VAMC, Assoc. Prof of Medicine, Duke University, Durham, NC</p>
<b>10:25 – 10:50 am</b>	<b>NATIONAL DATA SYSTEM</b>	<b>John Quinn</b>
	<p><i>Objectives:</i></p> <ol style="list-style-type: none"> <li>1. Describe the process of moving data from Vista to Corporate Data Warehouse.</li> <li>2. Demonstrate how a user might approach understanding the data and its organization in CDW.</li> <li>3. Delineate the general data access process for health operations, preparatory to research, and research.</li> </ol>	<p>Director, National Data Systems, Health Information Governance, VHA Office of Informatics and Analytics, Washington, DC</p>
<b>10:50 – 11:15 am</b>	<b>ENRICHING CANCER RESEARCH WITH INFORMATION FROM CLINICAL NOTES AND REPORTS</b>	<b>Scott Duvall, PhD</b>
	<p><i>Objectives:</i></p> <ol style="list-style-type: none"> <li>1. State how information from text in a patient's medical record can supplement available cancer data elements.</li> <li>2. Describe the VA Informatics and Computing Infrastructure (VINCI) and the tools available for chart review and natural language processing</li> <li>3. Describe the genetic diagnostic test data set and its potential for research use</li> </ol>	<p>Associate Director, VA Informatics and Computing Infrastructure VA Salt Lake City Health Care System, University of Utah School of Medicine and College of Pharmacy</p>
<b>11:15 – 11:40 pm</b>	<b>DATA AND INFORMATICS RESOURCES TO SUPPORT COMPARATIVE EFFECTIVENESS RESEARCH IN CANCER</b>	<b>Denise M. Hynes, MPH, PhD, RN</b>
	<p><i>Objectives:</i></p> <ol style="list-style-type: none"> <li>1. Describe data assets and methods available in VHA for CER</li> <li>2. Highlight select research examples of research focused on treatment trends and costs of breast and colon cancer treatments.</li> <li>3. List resources available through the VA Information Resource Center (VIREC) to facilitate CER in cancer</li> </ol>	<p>VA Research Career Scientist and Director, VA Information Resource Center, Hines IL. Professor, College of Medicine; Research Affiliate, School of Public Health; and, Biomedical Informatics Core Director, Center for Clinical and Translational Sciences (CCTS), University of Illinois, Chicago, IL</p>

**11:40 – 12:00 pm**    **PANEL DISCUSSION**

12:00 – 1:00 pm    **LUNCH/BUSINESS MEETING (Members Only)**

**CONCURRENT SESSION A: BRAIN MALIGNANCIES**

Moderator: David Adamson, MD

(1:00 – 3:00 PM)

1:00 – 1:05 pm	<b>PATIENT OR FAMILY MEMBER</b>	
1:05 – 1:30 pm	<b>SURGICAL ASPECT OF THE CENTRAL NERVOUS SYSTEM (CNS) METASTASIS</b> <i>Objectives:</i> <i>1. Identify patients for whom urgent neurosurgical consult is indicated.</i> <i>2. Identify patients who will benefit from surgical resection of brain metastasis.</i> <i>3. Delineate the benefits of surgical resection of brain metastasis.</i>	<b>Corey D. Adamson, MD</b> Chief of Neurosurgery, Associate Professor of Neurosurgery and Neurobiology Durham VA Medical Center; Duke University, Durham, NC
1:30 – 1:55 pm	<b>SYSTEMIC TREATMENT OF BRAIN METASTASIS</b> <i>Objectives:</i> <i>1. Predict the prognosis of patients with CNS metastasis.</i> <i>2. Interpret the effect of the blood/brain barrier on Chemotherapy.</i> <i>3. Describe the effectiveness of chemotherapy in CNS metastasis.</i>	<b>Peter Silberstein, MD</b> Chief, Oncology Omaha VA Medical Center, Omaha, NE
1:55 – 2:20 pm	<b>THE ROLE OF RADIATION THERAPY IN THE TREATMENT OF BRAIN METASTASES</b> <i>Objectives:</i> <i>1. Describe the epidemiology and diagnosis of brain metastases and accompanying signs and symptoms.</i> <i>2. Identify the key attributes of radiotherapy for brain metastases, specifically whole-brain radiotherapy (WBRT) versus stereotactic radiosurgery.</i> <i>3. Delineate the outcomes of WBRT and SRS for brain metastases, including local control, distant failure in the brain and normal tissue complications.</i>	<b>John Kirkpatrick MD, PhD</b>  Clinical Director & Associate Professor – Radiation Oncology Assistant Professor Neurosurgery The Preston Robert, Tisch Brain Tumor Center Duke Cancer Institute Durham, NC
2:20 – 2:45 pm	<b>QUALITY OF LIFE ISSUES IN PATIENTS WITH BRAIN METASTASES</b> <i>Objectives:</i> <i>1. Identify risk groups and discuss metastatic disease in the Central Nervous System.</i> <i>2. Discuss treatment options and associated adverse effects.</i> <i>3. Discuss quality of life issues specific to this population.</i>	<b>Maciej Mrugala, MD, PhD, MPH</b> Associate Professor of Neurology, University of Washington, Seattle, WA

<b>CONCURRENT SESSIONS B: SYMPTOM MANAGEMENT</b> Moderator: Mary Thomas, RN, MS, AOCN (1:00 – 3:00 PM)		
<b>1:00 – 1:35 pm</b>	<b>MANAGEMENT OF BOWEL OBSTRUCTION</b>	<b>Jocelyn White, MD, FAAPP, FACP, FAAHPM</b>
	<i>Objectives:</i> 1. Determine appropriate strategies to manage bowel obstruction. 2. Evaluate relevance of these strategies based in unique characteristics of the patient, malignancy, current cancer treatment, and patient’s goals of care. 3. Identify non-pharmacologic modalities to manage these symptoms.	Medical Director Legacy Hospice, Portland, OR
<b>1:35 – 2:10 pm</b>	<b>RESPIRATORY DIFFICULTIES: HUFF &amp; PUFF BUT OXYGEN AIN’T ENOUGH</b>	<b>Gary Hsin, MD, FAAHPM</b>
	<i>Objectives:</i> 1. Determine appropriate strategies to manage dyspnea based on underlying pathophysiology. 2. Evaluate these strategies based on unique characteristics of the patient, disease, ongoing treatment, and patient’s goals of care 3. Identify both pharmacologic and non-pharmacologic modalities for management	Medical Director, Hospice & Palliative Care Center, VA Palo Alto Health Care System Clinical Assistant Professor, Stanford University School of Medicine, Palo Alto, CA
<b>2:10 – 2:45 pm</b>	<b>MANAGEMENT OF STEROID INDUCED HYPERGLYCEMIA IN CANCER PATIENTS</b>	<b>Sonali Thosani, MD</b>
	<i>Objectives:</i> 1. Describe types of hyperglycemia in cancer patient population. 2. Describe risk factors for hyperglycemia and clinical factors to consider prior to treatment initiation. 3. Identify both pharmacologic and non-pharmacologic modalities for management.	Assistant Professor Department of Endocrine Neoplasia & HD The University of Texas MD Anderson Cancer Center, Houston, TX
<b>2:45 – 3:00 pm</b>	<b>PANEL DISCUSSION</b>	

3:00 – 3.30 pm

BREAK/VISIT EXHIBITORS

<b>BREAKOUT SESSIONS</b> (3:30 – 5:00 PM)		
Breakout 1	<b>PALLIATIVE CARE</b>	Drs. White/Hsin
Breakout 2	<b>CANCER REGISTRAR</b>	Frederick L. Greene, MD, FACS

	<p><i>Objective:</i></p> <ol style="list-style-type: none"> <li>1. Present FORDS Manual Revision with NCDB Data Collection updates.</li> <li>2. Describe AJCC staging</li> <li>3. To receive feedback from the VA Cancer registrars/programs regarding the changes to FORDS.</li> </ol>	
Breakout 3	<b>NAVIGATION/SURVIVORSHIP</b>	Julie Beck, RN, MSN, MPH, APRN-BC
Breakout 4	<b>CLINICAL TRIALS/ RESEARCH</b>	Nirmala Bhoopalam, MD
Breakout 5	<b>RADIATION ONCOLOGY</b>	Ruchika Gutt, MD

5:30 – 7:00 pm	<b>RECEPTION/EXHIBIT DISPLAYS/POSTER</b>	
7:00 – 8:00 pm	<b>ANNUAL DINNER/PRESIDENTIAL ADDRESS</b>	
8:00 – 9:00 pm	<b>KEYNOTE SPEAKER: MANAGEMENT OF CANCER IN THE OLDER CANCER PATIENT</b>	<b>Lodovico Balducci, MD</b>
	<p><i>Objectives:</i></p> <ol style="list-style-type: none"> <li>1. Distinguish physiologic age from chronological age.</li> <li>2. Design personalized treatment of cancer in the older aged person.</li> <li>3. Explain the interactions of age and cancer biology.</li> <li>4. Describe palliative care of the older patients</li> </ol>	<p>Senior Member and Program Leader Geriatric Oncology, Moffitt Cancer Center Tampa Professor of Oncological Sciences and Medicine University of South Florida College of Medicine, Tampa, FL</p>

## SUNDAY, SEPTEMBER 14, 2014

TIME	EVENT/TALK	SPEAKER/MODERATOR
7:00 – 12:00 pm	Registration	
7:00 – 12:00 pm	Exhibit Displays	
7:00 – 12:00 pm	General Poster Session	
7:00 – 8:30 am	Breakfast Buffet	

SESSION V: ABSTRACT SESSION		
Moderator: Joao Ascensao, MD, Ph.D (7:30 – 9:00 AM)		
7:30 – 7:45 am	<b>SYSTEMS AUTOMATION FOR CANCER SURVEILLANCE; A USEFUL TOOL FOR TRACKING THE CARE OF HEAD AND NECK CANCER PATIENTS IN THE EAR, NOSE, AND THROAT CLINIC</b>	Flores B, Price GW Raymond Murphy VAMC, Albuquerque, NM
	<i>Objectives:</i>	
7:45 – 8:00 am	<b>PREVENTING SKELETAL RELATED EVENTS IN VETERANS ON BISPSPHONATES FOR BONE METASTASES</b>	Malhotra S, Simeunovic K, Chanchorn E, Park YHA J. J. Peters VA Medical Center, Bronx, NY
	<i>Objectives:</i>	
	1. Assess screening dental evaluation prior to	

	<p><i>treatment in patients on bisphosphonates</i></p> <p>2. <i>Describe calcium and vitamin D co-prescribing in patients on bisphosphonates</i></p> <p>3. <i>Measure effectiveness of calcium and vitamin D supplementation</i></p>	
<b>8:00 – 8:15 am</b>	<b>THE USE AND BELIEFS OF COMPLEMENTARY AND ALTERNATIVE MEDICINE AMONG VETERAN CANCER PATIENTS</b>	Wang C, Bowman N, Neelam R, Cease K, Jolly S University of Michigan Medical School, Ann Arbor, MI
	<i>Objectives:</i>	
<b>8:15 – 8:30 am</b>	<b>BREAST CANCER TREATMENT AMONG RURAL AND URBAN WOMEN AT THE VETERANS HEALTH ADMINISTRATION</b>	Colonna S, Halwani A, Ying J, Sweeney C, Buys S Huntsman Cancer Institute, University of Utah Department of Internal Medicine, George E. Whalen VAMC, Salt Lake City, UT
	<i>Objectives:</i>	
	<p>1. <i>Recognize the demographics of rural and urban women with breast cancer at the VA</i></p> <p>2. <i>Understand the rural/urban classification scheme</i></p> <p>3. <i>Understand where breast cancer treatments among rural and urban women differ</i></p>	
<b>8:30 – 8:45 am</b>	<b>IMPLEMENTATION OF DISTRESS SCREENING AND MANAGEMENT IN MULTIPLE SPECIALTY CANCER CARE CLINICS</b>	Dimick J, Berman SP, Smith J, Curry S, Arfons L, Woods K, Savinell R, Mazanec P Louis Stokes Cleveland VA Medical Center, Cleveland, OH
	<i>Objectives:</i>	

8:45 – 9:15 am      **BREAK/VISIT EXHIBITS**

<b>SESSION VI: PROSTATE CANCER TUMOR BOARD</b> Moderator: Anita Aggarwal, MD (9:15 – 11:30 AM)		
<b>9:15 – 9:45 am</b>	<b>PROSTATE CANCER IN ELDERLY</b>	<b>Wayne Harris, MD</b>
	<p><i>Objectives:</i></p> <p>1. <i>Interpret issues of prostate cancer screening specific to elderly patients.</i></p> <p>2. <i>Discuss the role of therapy on hormone responsive and castrate resistant prostate cancer.</i></p> <p>3. <i>Interpret the findings of these studies vis-à-vis the elderly patient population.</i></p>	Emory University School of Medicine Winship Cancer Institute Atlanta, GA
<b>9:45 – 10:15 am</b>	<b>UPDATE ON ADVANCED PROSTATE CANCER</b>	<b>Tomasz Beer, MD</b>
	<i>Objectives:</i>	Professor of Medicine,



	<p><i>1. Interpret the biologic basis for modern hormonal therapy in prostate cancer.</i></p> <p><i>2. Describe endocrine pathways role in the progression of prostate cancer and resistance to androgen deprivation treatment.</i></p> <p><i>3. Use data from clinical trials in metastatic castration resistant prostate cancer to change current practice.</i></p>	Hematology & Medical Oncology and Deputy Director OHSU Knight Cancer Institute, Portland, OR
10:15 – 10:45 am	<b>ADVANCES IN RADIATION THERAPY FOR PROSTATE CANCER</b>	<b>Arthur Hung, MD</b>
	<p><i>Objectives:</i></p> <p><i>1. Identify the basic radiation techniques for prostate cancer.</i></p> <p><i>2. Delineate new options for shorter treatment courses.</i></p> <p><i>3. Interpret the effectiveness of adding radiation to surgery to improve outcomes for patients with advanced prostate cancer.</i></p>	Department of Radiation Medicine, Oregon Health & Science University, Portland, OR
10:45 – 11:15 am	<b>POST PROSTATECTOMY INCONTINENCE: WHAT CAN BE DONE</b>	<b>John P. Lavelle, MD</b>
	<p><i>Objectives:</i></p> <p><i>1. Describe the incidence and diagnosis of post prostatectomy incontinence.</i></p> <p><i>2. Explain conservative management of incontinence.</i></p> <p><i>3. Explain operative management of post prostatectomy incontinence.</i></p>	Associate Professor of Urology VA Palo Alto Health Care System / Stanford University, Palo Alto, CA
11:15 – 11:30 am	<b>PANEL DISCUSSION</b>	

**11:30 am**

**ADJOURN**

**11:30 am**

AVAHO Board Post Meeting/Lunch